NCT05739591 Long-term Safety and Efficacy of GBG Study Participants
| NCT ID | NCT05739591 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GBG Forschungs GmbH |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-10-12 |
| Primary Completion | 2030-05-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2022-10-12 with a primary completion date of 2030-05-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.
Eligibility Criteria
Inclusion criteria: * Participation and treatment in a GBG clinical trial for early breast cancer. * Prospective registration: Written informed consent according to local regulatory requirements prior to data and biomaterial collection. Exclusion criteria: * Participation and treatment in a non-GBG clinical trial for early breast cancer. * Patients with advanced or metastatic breast cancer who have participated and received treatment in a GBG clinical trial.
Contact & Investigator
Sibylle Loibl, Prof. Dr.
STUDY CHAIR
GBG Forschungs GmbH
Frequently Asked Questions
Who can join the NCT05739591 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05739591 currently recruiting?
Yes, NCT05739591 is actively recruiting participants. Contact the research team at eternity@gbg.de for enrollment information.
Where is the NCT05739591 trial being conducted?
This trial is being conducted at Innsbruck, Austria, Linz, Austria, Salzburg, Austria.
Who is sponsoring the NCT05739591 clinical trial?
NCT05739591 is sponsored by GBG Forschungs GmbH. The principal investigator is Sibylle Loibl, Prof. Dr. at GBG Forschungs GmbH. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.